Ecomac Remedies Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 08-12-2024
- Paid Up Capital ₹ 1.50 M
as on 08-12-2024
- Company Age 15 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.76 Cr
as on 08-12-2024
- Satisfied Charges ₹ 2.50 Cr
as on 08-12-2024
- Revenue %
(FY 2022)
- Profit 99.74%
(FY 2022)
- Ebitda 99.77%
(FY 2022)
- Net Worth -0.13%
(FY 2022)
- Total Assets %
(FY 2022)
About Ecomac Remedies
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M.
The company currently has active open charges totaling ₹6.76 Cr. The company has closed loans amounting to ₹2.50 Cr, as per Ministry of Corporate Affairs (MCA) records.
Kirti Jain and Gourav Jain serve as directors at the Company.
- CIN/LLPIN
U33100MH2009PTC192588
- Company No.
192588
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 May 2009
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Ecomac Remedies?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kirti Jain  | Director | 16-Apr-2018 | Current |
| Gourav Jain | Director | 16-Apr-2018 | Current |
Financial Performance and Corporate Structure Insights of Ecomac Remedies.
Ecomac Remedies Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 99.74% increase in profit. The company's net worth dipped by a decrease of 0.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ecomac Remedies?
In 2020, Ecomac Remedies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Union Bank Of India Creation Date: 23 Dec 2013 | ₹1.26 Cr | Open |
Union Bank Of India Creation Date: 03 Jul 2012 | ₹5.00 M | Open |
Union Bank Of India Creation Date: 22 Mar 2012 | ₹3.50 Cr | Open |
How Many Employees Work at Ecomac Remedies?
Ecomac Remedies has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ecomac Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ecomac Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
